# A Study of GnP RegimenCombined With Serplulimab and Stereotactic Body Radiation Therapy as First-line Treatment for Locally Advanced Pancreatic Cancer

> **NCT07101679** · PHASE2 · RECRUITING · sponsor: **West China Hospital** · enrollment: 23 (estimated)

## Conditions studied

- Locally Advanced Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** LICSBR

## Key facts

- **NCT ID:** NCT07101679
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-16
- **Primary completion:** 2027-04-15
- **Final completion:** 2029-04-15
- **Target enrollment:** 23 (ESTIMATED)
- **Last updated:** 2025-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07101679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07101679, "A Study of GnP RegimenCombined With Serplulimab and Stereotactic Body Radiation Therapy as First-line Treatment for Locally Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07101679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*